- Home
- CCO vs ANAB Comparison
CCO vs ANAB Comparison
Compare CCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCO
- ANAB
- Stock Information
- Founded
- CCO 1995
- ANAB 2005
- Country
- CCO United States
- ANAB United States
- Employees
- CCO N/A
- ANAB N/A
- Industry
- CCO Advertising
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CCO Consumer Discretionary
- ANAB Health Care
- Exchange
- CCO Nasdaq
- ANAB Nasdaq
- Market Cap
- CCO 616.3M
- ANAB 630.2M
- IPO Year
- CCO 2005
- ANAB 2017
- Fundamental
- Price
- CCO $1.32
- ANAB $22.98
- Analyst Decision
- CCO Hold
- ANAB Buy
- Analyst Count
- CCO 6
- ANAB 10
- Target Price
- CCO $1.75
- ANAB $48.00
- AVG Volume (30 Days)
- CCO 3.2M
- ANAB 419.0K
- Earning Date
- CCO 10-30-2025
- ANAB 11-04-2025
- Dividend Yield
- CCO N/A
- ANAB N/A
- EPS Growth
- CCO N/A
- ANAB N/A
- EPS
- CCO 0.04
- ANAB N/A
- Revenue
- CCO $1,538,895,000.00
- ANAB $123,164,000.00
- Revenue This Year
- CCO $6.16
- ANAB $11.22
- Revenue Next Year
- CCO $3.19
- ANAB $8.35
- P/E Ratio
- CCO $30.24
- ANAB N/A
- Revenue Growth
- CCO 31.61
- ANAB 304.17
- 52 Week Low
- CCO $0.81
- ANAB $12.21
- 52 Week High
- CCO $1.77
- ANAB $40.70
- Technical
- Relative Strength Index (RSI)
- CCO 57.90
- ANAB 58.97
- Support Level
- CCO $1.24
- ANAB $20.61
- Resistance Level
- CCO $1.43
- ANAB $23.64
- Average True Range (ATR)
- CCO 0.06
- ANAB 0.98
- MACD
- CCO 0.00
- ANAB 0.43
- Stochastic Oscillator
- CCO 45.24
- ANAB 85.59
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).